SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.890
-0.100 (-2.51%)
Apr 23, 2026, 2:27 PM EDT - Market open
SAB Biotherapeutics Market Cap
SAB Biotherapeutics has a market cap or net worth of $273.37 million as of April 23, 2026. Its market cap has increased by 2,551.36% in one year.
Market Cap
273.37M
Enterprise Value
189.76M
1-Year Change
2,551.36%
Ranking
Category
Stock Price
$3.89
Market Cap Chart
Since February 9, 2021, SAB Biotherapeutics's market cap has increased from $130.75M to $273.37M, an increase of 109.07%. That is a compound annual growth rate of 15.24%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 22, 2026 | 280.40M | 57.48% |
| Dec 31, 2025 | 178.05M | 408.46% |
| Dec 31, 2024 | 35.02M | -44.79% |
| Dec 29, 2023 | 63.43M | 113.36% |
| Dec 30, 2022 | 29.73M | -91.24% |
| Dec 31, 2021 | 339.54M | 159.68% |
| Feb 9, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| NovaBridge Biosciences | 294.90M |
| Eledon Pharmaceuticals | 293.23M |
| Cybin | 290.21M |
| C4 Therapeutics | 289.81M |
| Protara Therapeutics | 289.35M |
| Artiva Biotherapeutics | 288.69M |
| Cellectis | 283.29M |
| Zentalis Pharmaceuticals | 275.92M |